NuCana Approaches Critical Clinical and Financial Juncture

Financial Position: A Mixed Picture with Extended Runway

Biopharmaceutical company NuCana faces a period of significant catalysts and challenges. With crucial clinical data on the horizon and a recently strengthened balance sheet, the final months of the year are poised to determine whether the company achieves a decisive breakthrough or continues to navigate a landscape of uncertainty.

The company’s second quarter 2025 financial results painted a complex picture. NuCana reported a net loss of £24.1 million, a figure substantially impacted by a £12.6 million non-cash charge related to the revaluation of warrants issued during its May financing round.